000280893 001__ 280893
000280893 005__ 20250907001916.0
000280893 0247_ $$2doi$$a10.1136/jnnp-2024-333590
000280893 0247_ $$2pmid$$apmid:39107038
000280893 0247_ $$2pmc$$apmc:PMC12015049
000280893 0247_ $$2ISSN$$a0022-3050
000280893 0247_ $$2ISSN$$a0266-8637
000280893 0247_ $$2ISSN$$a0368-329X
000280893 0247_ $$2ISSN$$a1468-330X
000280893 0247_ $$2ISSN$$a2753-0477
000280893 0247_ $$2ISSN$$a2753-0485
000280893 0247_ $$2altmetric$$aaltmetric:166142000
000280893 037__ $$aDZNE-2025-00977
000280893 041__ $$aEnglish
000280893 082__ $$a610
000280893 1001_ $$00000-0002-0945-0724$$aBuchert, Ralph$$b0
000280893 245__ $$aAdded value of FDG-PET for detection of progressive supranuclear palsy.
000280893 260__ $$aLondon$$bBMJ Publishing Group$$c2025
000280893 3367_ $$2DRIVER$$aarticle
000280893 3367_ $$2DataCite$$aOutput Types/Journal article
000280893 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756280749_29818
000280893 3367_ $$2BibTeX$$aARTICLE
000280893 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000280893 3367_ $$00$$2EndNote$$aJournal Article
000280893 520__ $$aDiagnostic criteria for progressive supranuclear palsy (PSP) include midbrain atrophy in MRI and hypometabolism in [18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) as supportive features. Due to limited data regarding their relative and sequential value, there is no recommendation for an algorithm to combine both modalities to increase diagnostic accuracy. This study evaluated the added value of sequential imaging using state-of-the-art methods to analyse the images regarding PSP features.The retrospective study included 41 PSP patients, 21 with Richardson's syndrome (PSP-RS), 20 with variant PSP phenotypes (vPSP) and 46 sex- and age-matched healthy controls. A pretrained support vector machine (SVM) for the classification of atrophy profiles from automatic MRI volumetry was used to analyse T1w-MRI (output: MRI-SVM-PSP score). Covariance pattern analysis was applied to compute the expression of a predefined PSP-related pattern in FDG-PET (output: PET-PSPRP expression score).The area under the receiver operating characteristic curve for the detection of PSP did not differ between MRI-SVM-PSP and PET-PSPRP expression score (p≥0.63): about 0.90, 0.95 and 0.85 for detection of all PSP, PSP-RS and vPSP. The MRI-SVM-PSP score achieved about 13% higher specificity and about 15% lower sensitivity than the PET-PSPRP expression score. Decision tree models selected the MRI-SVM-PSP score for the first branching and the PET-PSPRP expression score for a second split of the subgroup with normal MRI-SVM-PSP score, both in the whole sample and when restricted to PSP-RS or vPSP.FDG-PET provides added value for PSP-suspected patients with normal/inconclusive T1w-MRI, regardless of PSP phenotype and the methods to analyse the images for PSP-typical features.
000280893 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000280893 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x1
000280893 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000280893 650_7 $$2Other$$aIMAGE ANALYSIS
000280893 650_7 $$2Other$$aMOVEMENT DISORDERS
000280893 650_7 $$2Other$$aMRI
000280893 650_7 $$2Other$$aPET
000280893 650_7 $$2Other$$aSUPRANUCLEAR PALSY
000280893 650_7 $$00Z5B2CJX4D$$2NLM Chemicals$$aFluorodeoxyglucose F18
000280893 650_7 $$2NLM Chemicals$$aRadiopharmaceuticals
000280893 650_2 $$2MeSH$$aHumans
000280893 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: diagnostic imaging
000280893 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: pathology
000280893 650_2 $$2MeSH$$aFemale
000280893 650_2 $$2MeSH$$aMale
000280893 650_2 $$2MeSH$$aPositron-Emission Tomography: methods
000280893 650_2 $$2MeSH$$aFluorodeoxyglucose F18
000280893 650_2 $$2MeSH$$aAged
000280893 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000280893 650_2 $$2MeSH$$aRetrospective Studies
000280893 650_2 $$2MeSH$$aMiddle Aged
000280893 650_2 $$2MeSH$$aSupport Vector Machine
000280893 650_2 $$2MeSH$$aRadiopharmaceuticals
000280893 650_2 $$2MeSH$$aBrain: diagnostic imaging
000280893 650_2 $$2MeSH$$aBrain: pathology
000280893 650_2 $$2MeSH$$aAtrophy
000280893 7001_ $$00000-0003-3856-9094$$aHuppertz, Hans-Jürgen$$b1
000280893 7001_ $$00000-0002-9931-2666$$aWegner, Florian$$b2
000280893 7001_ $$00000-0001-5592-8373$$aBerding, Georg$$b3
000280893 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b4$$udzne
000280893 7001_ $$00000-0003-0290-7186$$aApostolova, Ivayla$$b5
000280893 7001_ $$00000-0001-8540-3789$$aBuhmann, Carsten$$b6
000280893 7001_ $$00000-0001-7680-2147$$aPoetter-Nerger, Monika$$b7
000280893 7001_ $$aDierks, Alexander$$b8
000280893 7001_ $$0P:(DE-2719)9001160$$aKatzdobler, Sabrina$$b9
000280893 7001_ $$00000-0002-3054-9905$$aKlietz, Martin$$b10
000280893 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b11
000280893 7001_ $$00000-0002-2053-9623$$aMahmoudi, Nima$$b12
000280893 7001_ $$00009-0008-8625-0217$$aRinscheid, Andreas$$b13
000280893 7001_ $$0P:(DE-2719)9002627$$aQuattrone, Andrea$$b14$$udzne
000280893 7001_ $$aRogozinski, Sophia$$b15
000280893 7001_ $$00000-0002-7357-713X$$aRumpf, Jost-Julian$$b16
000280893 7001_ $$0P:(DE-HGF)0$$aSchneider, Christine$$b17
000280893 7001_ $$0P:(DE-2719)9003671$$aStöcklein, Sophia$$b18$$udzne
000280893 7001_ $$00000-0001-7368-2354$$aSpetsieris, Phoebe G$$b19
000280893 7001_ $$00000-0002-0854-864X$$aEidelberg, David$$b20
000280893 7001_ $$0P:(DE-2719)2814810$$aSabri, Osama$$b21$$udzne
000280893 7001_ $$aBarthel, Henryk$$b22
000280893 7001_ $$00000-0001-9298-2897$$aWattjes, Mike P$$b23
000280893 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter$$b24$$eLast author
000280893 7001_ $$aInitiative, Alzheimer’s Disease Neuroimaging$$b25$$eCollaboration Author
000280893 773__ $$0PERI:(DE-600)1480429-3$$a10.1136/jnnp-2024-333590$$gVol. 96, no. 3, p. 287 - 295$$n3$$p287 - 295$$tJournal of neurology, neurosurgery, and psychiatry$$v96$$x0022-3050$$y2025
000280893 8564_ $$uhttps://pub.dzne.de/record/280893/files/DZNE-2025-00977%2BSUP.pdf$$yOpenAccess
000280893 8564_ $$uhttps://pub.dzne.de/record/280893/files/DZNE-2025-00977%2BSUP.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000280893 909CO $$ooai:pub.dzne.de:280893$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000280893 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000280893 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001160$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000280893 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000280893 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002627$$aExternal Institute$$b14$$kExtern
000280893 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003671$$aExternal Institute$$b18$$kExtern
000280893 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2814810$$aExternal Institute$$b21$$kExtern
000280893 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b24$$kDZNE
000280893 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000280893 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x1
000280893 9141_ $$y2025
000280893 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-28
000280893 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-28
000280893 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-28
000280893 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-28
000280893 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-28
000280893 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROL NEUROSUR PS : 2022$$d2024-12-28
000280893 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJ NEUROL NEUROSUR PS : 2022$$d2024-12-28
000280893 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-28
000280893 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000280893 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-28
000280893 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-28
000280893 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000280893 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-28
000280893 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2024-12-28$$wger
000280893 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-28
000280893 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-28
000280893 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-28
000280893 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x0
000280893 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x1
000280893 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x2
000280893 980__ $$ajournal
000280893 980__ $$aVDB
000280893 980__ $$aUNRESTRICTED
000280893 980__ $$aI:(DE-2719)1110007
000280893 980__ $$aI:(DE-2719)1111015
000280893 980__ $$aI:(DE-2719)1111016
000280893 9801_ $$aFullTexts